Advertisement

Picture [iito] No Tracking 650x80px
Organisation › Details

Orchard Therapeutics plc (Nasdaq: ORTX)

Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapies includes Strimvelis®, the first autologous ex vivo gene therapy approved by the European Medicines Agency for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Additional programs for neurometabolic disorders, primary immune deficiencies and hemoglobinopathies include three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD) and transfusion-dependent beta-thalassemia (TDBT), as well as an extensive preclinical pipeline. Orchard currently has offices in the U.K. and the U.S., including London, San Francisco and Boston. *

 

Period Start 2018-11-05 existent
  Group Orchard Therapeutics (Group)
  Predecessor Orchard Therapeutics Ltd.
Product Industry gene therapy
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 108 Cannon Street
  City EC4N 6EU London
  Tel +44-203-384-6700
    Address record changed: 2019-01-08
     
Basic data Employees n. a.
  Currency USD
  Annual sales 2,076,000 (sales, product, consolidated (2018) 2018-12-31)
  Profit -230,495,000 (2018-12-31)
  Cash 335,844,000 (2018-12-31)
     
    * Document for �About Section�: Orchard Therapeutics Ltd.. (1/7/19). "Press Release: Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy". Boston & London.
     
   
Record changed: 2020-08-04

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Orchard Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] No Content Marketing 650x80px




» top